Management of Drug-Induced Interstitial Lung Disease

EP. 1: Antibody Drug Conjugates and Interstitial Lung Disease Risk

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 2: Risks for Developing ILD and Personal Experience

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 3: Changes in Cancer Treatment and Management of ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 4: Use of Antibody Drug Conjugates and Potential for ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 5: Rate and Class Effect of ILD with Antibody Drug Conjugates

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 6: CDK 4/6 Inhibitors and Identifying ILD in Patients

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 7: Managing Patient Symptoms and Clinician Education

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 8: Drug-Induced ILD and Rate of Occurrence in GI Cancer Trials

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 9: Patient Factors for Developing ILD and Personal Experience

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 10: Patient Management upon Developing ILD and Education

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 11: Potential Risk of Drug-Induced Interstitial Lung Disease

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 12: Personal Experience with Drug-Induced ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 13: Rate of ILD and Monitoring Parameters

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 14: Identifying Drug-Induced ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 15: Patient Management and Educational Tools for ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 16: Role of Antibody Drug Conjugates and Personal Experience

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 17: Risks for Developing ILD in Gastrointestinal Cancer Studies

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 18: Risk of ILD as a Class Effect and Identifying ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 19: Changes in Treatment Goals due to Drug Induced ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 20: Management of Patients Who Develop ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 21: Educational Tools for Possible Drug-Induced ILD

ByTiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center,Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center,Axel Grothey, MD, West Cancer Center, University of Tennessee,Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins,Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

June 30th 2020

EP. 1: Antibody Drug Conjugates and Interstitial Lung Disease Risk

EP. 2: Risks for Developing ILD and Personal Experience

EP. 3: Changes in Cancer Treatment and Management of ILD

EP. 4: Use of Antibody Drug Conjugates and Potential for ILD

EP. 5: Rate and Class Effect of ILD with Antibody Drug Conjugates

EP. 6: CDK 4/6 Inhibitors and Identifying ILD in Patients

EP. 7: Managing Patient Symptoms and Clinician Education

EP. 8: Drug-Induced ILD and Rate of Occurrence in GI Cancer Trials

EP. 9: Patient Factors for Developing ILD and Personal Experience

EP. 10: Patient Management upon Developing ILD and Education

EP. 11: Potential Risk of Drug-Induced Interstitial Lung Disease

EP. 12: Personal Experience with Drug-Induced ILD

EP. 13: Rate of ILD and Monitoring Parameters

EP. 14: Identifying Drug-Induced ILD

EP. 15: Patient Management and Educational Tools for ILD

EP. 16: Role of Antibody Drug Conjugates and Personal Experience

EP. 17: Risks for Developing ILD in Gastrointestinal Cancer Studies

EP. 18: Risk of ILD as a Class Effect and Identifying ILD

EP. 19: Changes in Treatment Goals due to Drug Induced ILD

EP. 20: Management of Patients Who Develop ILD

EP. 21: Educational Tools for Possible Drug-Induced ILD

Trending on OncLive

FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC

HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts

Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC

SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma

Five Under 5: Top Oncology Videos for the Week of 1/25